CTOs on the Move

SyntheZyme

www.synthezyme.com

 
SyntheZyme develops bio-based products and technologies with a unique and competitive cost/performance. We work closely together with our industrial partners for the manufacture and marketing of our bio-based commodity and specialty products for the global market. We seek to complement our core competencies with those of our strategic, industrial partners. The success of our business is based on our capabilities to structure and operate entrepreneurial partnerships. SyntheZyme’s scientists and engineers have a deep knowledge in chemistry, synthetic biology, fermentation engineering and materials science with process know-how
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.synthezyme.com
  • 11 University Place D203
    Rensselaer, NY USA 12144
  • Phone: 908.305.4986

Executives

Name Title Contact Details

Similar Companies

Triad Life Sciences

Triad Life Sciences completes A$25m funding round, anticipates ASX listing in coming months – Learn More >> Triad Life Sciences® introduces InnovaMatrix™Technology Platform, a next-generation extracellular matrix (ECM) product that advance...

Michigan Medicine

Michigan Medicine, based in Ann Arbor, Michigan, is part of one of the world`s leading universities. Michigan Medicine is a premier, highly ranked academic medical center and award-winning health care system with state-of-the-art facilities. Our vision is to create the future of health care through scientific discovery, innovations in education, and the most effective and compassionate care.

bioStrategies Group

bioStrategies Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mana Therapeutics

MANA was founded in November 2018, based on the research and human proof-of-concept clinical trials conducted by Dr. Catherine Bollard and her team at Children`s National Hospital (CNH) in Washington, D.C., along with colleagues at Johns Hopkins Medical Center.

Libra Therapeutics

Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases.